Covestro (1COV) AGM 2025 summary
Event summary combining transcript, slides, and related documents.
AGM 2025 summary
2 Dec, 2025Opening remarks and agenda
AGM opened with reflections on global volatility, trade conflicts, and economic uncertainty, emphasizing the importance of adaptability and solution focus.
The meeting was held virtually, with all formalities, agenda, and technical arrangements detailed and compliant with legal requirements.
No requests for agenda additions or counter-motions were received; all required documents were made available in advance.
Financial performance review
Despite challenging conditions, full-year targets for 2024 were met, with a 7.4% increase in volume sold but sales slightly below the previous year due to low prices.
EBITDA remained stable at EUR 1.1 billion, but net income was negative at EUR -266 million, resulting in no dividend for 2024.
Free operating cash flow was positive at EUR 89 million, with strong Q4 performance; ROCE over WACC was -7.4 percentage points.
Performance materials saw a 12% revenue increase from higher volumes, while solutions and specialty segment volumes rose 4% but sales declined due to lower prices.
Board and executive committee updates
Monique Buch was appointed as the new Chief Commercial Officer, succeeding Sucheta Govil in August 2025.
Several changes occurred in the Supervisory Board, with new members joining and others retiring.
The Supervisory Board held five regular meetings, focusing on economic challenges and the XRG transaction.
Latest events from Covestro
- FY 2025 saw lower sales and earnings, but transformation and climate targets remain on track.1COV
Investor presentation26 Feb 2026 - EBITDA fell 30.9% to €740m as strategic actions and XRG partnership offset weak demand.1COV
Q4 2025 (Media)26 Feb 2026 - Sales and EBITDA declined sharply in FY 2025, but strategic initiatives and cost savings progressed.1COV
Q4 202526 Feb 2026 - Sales and EBITDA fell in Q3 2025, with guidance cut and acquisitions advancing.1COV
Q3 20253 Feb 2026 - Volume growth offset by lower prices; EBITDA fell and guidance narrowed as ADNOC talks progress.1COV
Q2 20242 Feb 2026 - €62/share offer and €1.17bn capital boost support growth, sustainability, and governance.1COV
Investor Update20 Jan 2026 - Q3 volume growth offset price declines; FY 2024 outlook narrowed amid margin pressure.1COV
Q3 202418 Jan 2026 - Stable EBITDA and volume growth offset price declines; XRG takeover and STRONG program drive outlook.1COV
Q4 20247 Jan 2026 - Q1 sales steady, EBITDA fell on one-offs; 2025 outlook narrowed as transformation and XRG progress.1COV
Q1 202525 Nov 2025